These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 2456047

  • 21. Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine.
    Asberg M, Ringberger VA, Sjöqvist F, Thorén P, Träskman L, Tuck JR.
    Clin Pharmacol Ther; 1977 Feb; 21(2):201-7. PubMed ID: 13959
    [Abstract] [Full Text] [Related]

  • 22. Toward a biochemical classification of depressive disorders. I. Differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depressions.
    Schildkraut JJ, Orsulak PJ, Schatzberg AF, Gudeman JE, Cole JO, Rohde WA, LaBrie RA.
    Arch Gen Psychiatry; 1978 Dec; 35(12):1427-33. PubMed ID: 727878
    [Abstract] [Full Text] [Related]

  • 23. Monoamine metabolites in CSF and suicidal behavior.
    Träskman L, Asberg M, Bertilsson L, Sjöstrand L.
    Arch Gen Psychiatry; 1981 Jun; 38(6):631-6. PubMed ID: 6166274
    [Abstract] [Full Text] [Related]

  • 24. The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients.
    Lundmark J, Wålinder J, Alling C, Manniche PM, Dalgaard L.
    Eur Neuropsychopharmacol; 1994 Mar; 4(1):1-6. PubMed ID: 7515737
    [Abstract] [Full Text] [Related]

  • 25. Consistent evidence for a biological subtype of depression characterized by low CSF monoamine levels.
    Gibbons RD, Davis JM.
    Acta Psychiatr Scand; 1986 Jul; 74(1):8-12. PubMed ID: 2429500
    [Abstract] [Full Text] [Related]

  • 26. Reliability of urinary monoamine and metabolite output measurements in depressed patients.
    Linnoila M, Karoum F, Miller T, Potter WZ.
    Am J Psychiatry; 1983 Aug; 140(8):1055-7. PubMed ID: 6191580
    [Abstract] [Full Text] [Related]

  • 27. Uncoupling of serotonergic and noradrenergic systems in depression: preliminary evidence from continuous cerebrospinal fluid sampling.
    Geracioti TD, Loosen PT, Ekhator NN, Schmidt D, Chambliss B, Baker DG, Kasckow JW, Richtand NM, Keck PE, Ebert MH.
    Depress Anxiety; 1997 Aug; 6(3):89-94. PubMed ID: 9442982
    [Abstract] [Full Text] [Related]

  • 28. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls.
    Gerner RH, Fairbanks L, Anderson GM, Young JG, Scheinin M, Linnoila M, Hare TA, Shaywitz BA, Cohen DJ.
    Am J Psychiatry; 1984 Dec; 141(12):1533-40. PubMed ID: 6209989
    [Abstract] [Full Text] [Related]

  • 29. Depressive mania versus agitated depression: biogenic amine and hypothalamic-pituitary-adrenocortical function.
    Swann AC, Stokes PE, Secunda SK, Maas JW, Bowden CL, Berman N, Koslow SH.
    Biol Psychiatry; 1994 May 15; 35(10):803-13. PubMed ID: 7519061
    [Abstract] [Full Text] [Related]

  • 30. Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients.
    Mann JJ, Malone KM.
    Biol Psychiatry; 1997 Jan 15; 41(2):162-71. PubMed ID: 9018386
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Urinary monoamines and monoamine metabolites in subtypes of unipolar depressive disorder and normal controls.
    Roy A, Pickar D, Douillet P, Karoum F, Linnoila M.
    Psychol Med; 1986 Aug 15; 16(3):541-6. PubMed ID: 3763772
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Catecholamine metabolism during heroin use.
    Schildkraut JJ, Meyer RE, Orsulak PJ, Mirin SM, Roffman M, Platz PA, Grab E, Randall ME, McDougle M.
    Am J Psychiatry; 1977 May 15; 134(5):534-7. PubMed ID: 848581
    [Abstract] [Full Text] [Related]

  • 35. High correlation of norepinephrine and its major metabolite excretion rates.
    Linnoila M, Karoum F, Potter WZ.
    Arch Gen Psychiatry; 1982 May 15; 39(5):521-3. PubMed ID: 7092485
    [Abstract] [Full Text] [Related]

  • 36. Pre-treatment neurotransmitter metabolites and response to imipramine or amitriptyline treatment.
    Maas JW, Kocsis JH, Bowden CL, Davis JM, Redmond DE, Hanin I, Robins E.
    Psychol Med; 1982 Feb 15; 12(1):37-43. PubMed ID: 6177015
    [Abstract] [Full Text] [Related]

  • 37. Urinary excretion of catecholamines and their metabolites in relation to circulating catecholamines. Six-hour infusion of epinephrine and norepinephrine in healthy volunteers.
    Moleman P, Tulen JH, Blankestijn PJ, Man in 't Veld AJ, Boomsma F.
    Arch Gen Psychiatry; 1992 Jul 15; 49(7):568-72. PubMed ID: 1627048
    [Abstract] [Full Text] [Related]

  • 38. Dystrobrevin-binding protein 1 gene (DTNBP1) variants associated with cerebrospinal fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in healthy volunteers.
    Andreou D, Saetre P, Kähler AK, Werge T, Andreassen OA, Agartz I, Sedvall GC, Hall H, Terenius L, Jönsson EG.
    Eur Neuropsychopharmacol; 2011 Sep 15; 21(9):700-4. PubMed ID: 21295953
    [Abstract] [Full Text] [Related]

  • 39. A study of biogenic amine metabolites in the cerebrospinal fluid and urine of monkeys with chlorpromazine-induced dyskinesia.
    Messiha FS.
    J Neurol Sci; 1974 Jan 15; 21(1):39-46. PubMed ID: 4216622
    [No Abstract] [Full Text] [Related]

  • 40. Analysis of monoamines in the cerebrospinal fluid of Chinese patients with Alzheimer's disease.
    Liu HC, Yang JC, Chang YF, Liu TY, Chi CW.
    Ann N Y Acad Sci; 1991 Jan 15; 640():215-8. PubMed ID: 1723257
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.